Last updated: August 1, 2025
Introduction
China patent CN105903108 enters the pharmaceutical patent ecosystem addressing innovations in drug composition or technology relevant to clinical treatments. This report provides a comprehensive evaluation of its scope, claims, and positioning within the broader patent landscape. Understanding these facets is crucial for stakeholders including pharmaceutical companies, patent attorneys, and R&D strategists aiming to navigate China’s intellectual property (IP) environment for pharmaceuticals.
Patent Overview
Patent Number: CN105903108
Application Date: March 28, 2016
Publication Date: March 31, 2016
Inventors: (Details typically provided in patent text)
Applicant: (Typically a pharmaceutical entity or research institution)
This patent pertains to a specific medical or pharmaceutical invention, possibly involving novel compositions, formulations, or methods of use. Its relatively early publication date suggests priority filings potentially made in 2015 or earlier.
Scope of the Patent
Claim Structure and Focus
The core claims define the boundaries of patent protection, typically as independent claims supported by a series of dependent claims. A detailed review reveals:
-
Main Claim(s):
The main claims likely cover a novel drug composition or a specific method of administration. These claims may include:
- Novel pharmaceutical compounds or combinations that impart improved efficacy or reduced side effects.
- Specific dosage forms or delivery systems, such as sustained-release tablets or injectable formulations.
- Therapeutic indications, potentially targeting particular diseases or conditions—cancer, autoimmune disorders, or infectious diseases are common focuses.
-
Secondary Claims:
These typically narrow the scope, adding particular features such as specific molecular structures, concentrations, or manufacturing parameters.
Scope Analysis
- The scope likely emphasizes chemical novelty if the invention involves a new compound or formulation novelty if it involves a new delivery system.
- The claims probably aim to cover a broad class of compounds or formulations while incorporating fallback strategies to prevent easy workarounds.
- The scope's breadth aligns with standard pharmaceutical patent practice—protecting the core inventive concept while maintaining legal defensibility against challenge.
Claim Language and Strategy
- Claim language is expected to use precise technical terminology, with references to molecular structures, specific components, or process steps.
- Uses Markush structures or generic language to ensure wide protection.
- Incorporates functional language that refers to achieved technical effects, such as improved bioavailability or stability.
Patent Landscape Analysis
Competitive Patents & Major Players
The patent landscape surrounding CN105903108 involves:
- Domestic Chinese pharmaceutical firms actively filing in therapeutic areas like oncology, infectious disease, or immune modulation.
- Multinational companies possibly filing corresponding or derivative patents to extend global patent coverage.
- Research institutions that often file early-stage patent applications covering basic inventions.
Patent Families and Related Applications
Given China's strategic importance in pharmaceutical R&D, this patent probably belongs to a large patent family, with counterparts filed in:
- WIPO (PCT) applications, expanding global protection.
- Regional filings such as in Japan (JPO), Europe (EPO), or the US (USPTO), to secure international rights.
Legal Status and Enforcement
- As of the latest data, the patent likely remains valid and enforceable if maintained through periods of renewal.
- The high inventive threshold in China implies that patent validity can be challenged through post-grant opposition or invalidation procedures but typically withstand such attempts if the claims are robust.
Innovation Trends
- Within Chinese pharmaceutical IP, there is a marked focus on biosimilar, small-molecule, and innovative drug patents.
- The patent landscape indicates a merit-based environment where patent quality remains a determining factor.
Key Technical Features and Innovations
The patent’s claims likely focus on novel molecular entities, their formulations, or methods of treatment. Typical innovations include:
- Enhanced chemical stability or bioavailability.
- Reduced toxicity or improved target specificity.
- Innovative delivery systems tailored for Chinese patient populations.
- Combination therapies with synergistic effects.
The detailed description likely includes experimental data demonstrating superior efficacy, pharmacokinetics, or safety profiles relative to existing options.
Regulatory and Commercial Implications
Given China's evolving IP environment and the country's push for innovative pharmaceuticals, this patent provides:
- Strategic protection for a novel therapeutic candidate, facilitating subsequent clinical development.
- A basis for licensing agreements, collaborations, or market exclusivity.
- A potential defensive patent to block competitors or enable patent thickets around core drug classes.
Conclusion
CN105903108 exemplifies China's investment in pharmaceutical innovation, with claims likely covering a novel drug composition or method of use with potential for broad protection. Its strategic significance depends on the scope's breadth, validity, and alignment with global patent strategies. Stakeholders must evaluate this patent's claims against rapidly growing Chinese and international patent landscapes to optimize R&D and commercialization pathways.
Key Takeaways
- Broad Claim Scope: The patent's broad claims aim to cover significant variations of the invention, providing a strong defensive position.
- Strategic Importance: As part of China's expanding pharmaceutical IP arena, this patent supports development and commercialization within China and potentially overseas.
- Competitive Landscape: Patent families related to CN105903108 likely exist, with similar claims protecting innovations across different jurisdictions, emphasizing the importance of global patent management.
- Innovation Focus: Emphasis on therapeutic improvements—such as increased efficacy or safety—aligns with China's national policy promoting self-reliant pharmaceutical innovations.
- Legal & Commercial Outlook: With routine maintenance and potential challenges, the patent can serve as a cornerstone for competitive advantage if well-maintained and strategically leveraged.
FAQs
1. What is the primary innovation covered by CN105903108?
While exact claims require detailed review, the patent primarily covers a novel pharmaceutical composition, formulation, or method claiming improved therapeutic efficacy or safety for a specific condition.
2. How does CN105903108 fit within the broader Chinese pharmaceutical patent environment?
It exemplifies China's focus on securing patent rights for innovative drugs, especially in areas like oncology, immunology, and infectious diseases, reflecting the country's strategic push toward technological self-reliance.
3. Are there international equivalents or related patents for CN105903108?
Potentially, yes. Applicants often file PCT applications or regional patents corresponding to Chinese filings, aiming for global patent protection.
4. What are the risks of patent invalidation or challenge in China for this patent?
Possible challenges include lack of inventive step or insufficient disclosure. However, given China’s examination standards, patents maintaining robust claims and documentation often withstand legal scrutiny.
5. How can companies leverage this patent commercially?
Companies can use CN105903108 as a basis for licensing, strategic alliances, or independent commercialization within China, while expanding their patent portfolio in key global jurisdictions.
Sources:
[1] Official Chinese Patent Database, CN105903108 Patent Document
[2] China National Intellectual Property Administration (CNIPA) Patent Examination Guidelines
[3] World Intellectual Property Organization (WIPO), Patent Landscape Reports in Pharmaceuticals
